Granted Patent
B2
US 12,486,318 · App. 16/310,326 · Granted Dec 2, 2025
Anti-guanosine antibody as a molecular delivery vehicle
Assignee:
YALE UNIVERSITY
C07K16/18A61K9/141A61K9/513A61K31/704A61K47/65A61K47/6843A61K47/6907A61K47/6929A61K49/0002C07K2317/24C07K2317/565C07K2317/569C07K2317/622C07K2317/626
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Guanosine-targeted nanocarriers for encapsulating an active agent and delivering it to extracellular guanosine and DNA are provided. The nanocarriers, for example, polymeric particles, liposomes, and multilamellar vesicles have targeting moiety that targets guanosine attached, linked, or conjugated thereto. The targeting moiety that targets guanosine is typically an antibody, or variant, fragment, or fusion protein derived therefrom that binds to guanosine. The targeting moiety can be a circulating autoantibody that binds guanosine such as those commonly found in patients with SLE. Cytoplasmic delivery vehicles that do not localize into endosomes or lysosomes are also provided. The delivery agent is typically an antibody, or variant, fragment, or fusion protein derived therefrom that binds to guanosine. In some embodiments, the targeting moiety or delivery agent is antibody 4H2 or a variant, fragment, or fusion protein derived therefrom. Pharmaceutical compositions, methods of use, and dosage regimens are also provided.
Claims (27)
1 . A nanocarrier comprising a nanoparticle comprising a targeting moiety conjugated or linked to the outer surface thereof and a cytotoxic agent encapsulated therein,
wherein the targeting moiety consists of an effective amount of a plurality of molecules of an antibody that binds to extracellular guanosine to increase localization of the nanocarrier to extracellular guanosine relative to the same nanocarrier in the absence of the targeting moiety,
wherein the nanocarrier is free from unconjugated antibody, and
wherein the nanocarrier creates a positive feedback loop that stimulates increased localization of the nanocarrier to the extracellular guanosine over time in vivo when administered to subject.
2 . The nanocarrier of claim 1 , wherein the antibody is an intact immunoglobulin, or a mono-, di-, or tri-valent or multivalent single chain variable fragment (scFv), an Fab, F(ab′) 2 , minibody, scFv-Fc, diabody, triabody, or tetrabody derived therefrom that comprises the complementarity-determining regions of the intact immunoglobulin and binds to guanosine.
3 . The nanocarrier of claim 1 , wherein the antibody comprises a heavy chain comprising the three complementarity-determining regions (CDR) of SEQ ID NO:5, and a light chain comprising the three CDR of SEQ ID NO:1.
4 . The nanocarrier of claim 3 , wherein the antibody is a mono-, di-, or tri-valent or multivalent single chain variable fragment (scFv), an Fab, F(ab′) 2 , minibody, scFv-Fc, diabody, triabody, or tetrabody.
5 . The nanocarrier of claim 1 , wherein the antibody comprises
(i) a heavy chain comprising the three complementarity-determining regions (CDR) of SEQ ID NO:5, and a light chain comprising the three CDR of SEQ ID NO:1; or
(ii) a heavy chain comprising the amino acid sequence from SEQ ID NO: 5, and a light chain comprising the amino acid sequence of SEQ ID NO:1; or
(iii) the scFv of SEQ ID NO:22.
6 . The nanocarrier of claim 1 , wherein the nanoparticle is selected from the group consisting of polymeric nanoparticle, liposome, and multilamellar vesicle.
7 . The nanocarrier of claim 6 , wherein the nanoparticle is a polymeric nanoparticle.
8 . The nanocarrier of claim 1 , further comprising one or more active agents encapsulated therein.
9 . A pharmaceutical composition comprising an effective amount of the nanocarrier of claim 1 .
10 . A method of detecting site or sites of cancer, tissue damage, injury, or ischemia comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 9 , wherein the one or more active agents is an agent that is detectable using diagnostic imaging or nuclear medicine techniques.
11 . A cytoplasmic molecular delivery vehicle consisting of an antibody that binds guanosine comprising a heavy chain comprising the three complementarity-determining regions (CDR) of SEQ ID NO:5, and a light chain comprising the three CDR of SEQ ID NO: 1 linked to a cargo,
wherein the delivery vehicle can deliver the cargo into the cytoplasm of cells and avoid localization to endosomes or lysosomes.
12 . The delivery vehicle of claim 11 , wherein the antibody is a mono-, di-, or tri-valent or multivalent single chain variable fragment (scFv), an Fab, F(ab′) 2 , minibody, scFv-Fc, diabody, triabody, or tetrabody.
13 . A pharmaceutical composition comprising an effective amount of the delivery vehicle of claim 11 .
14 . A method of detecting site or sites of cancer, tissue damage, injury, or ischemia comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition of claim 13 , wherein the cargo is an agent that is detectable using diagnostic imaging or nuclear medicine techniques.
15 . A single chain variable fragment comprising the amino acid sequence of SEQ ID NO:22.
16 . The nanocarrier of claim 8 , wherein the cytotoxic agent is a chemotherapeutic agent.
17 . The nanocarrier of claim 8 , wherein the cytotoxic agent is a radiosensitizer.
18 . The nanocarrier of claim 5 , wherein the nanocarrier can cross the blood-brain-barrier (BBB) following systemic administration to a mammalian subject.
19 . A polymeric nanoparticle comprising poly(lactic-co-glycolic acid)-poly(ε-carbobenzoxyl-L-lysine) (PLGA-PLL) and an antibody comprising a heavy chain comprising the three complementarity-determining regions (CDR) of SEQ ID NO:5, and a light chain comprising the three CDR of SEQ ID NO:1 conjugated to PLL and displayed on the exterior of the nanoparticle.
20 . The polymeric nanoparticle of claim 19 comprising an active agent encapsulated therein.
Continuity (2)
Provisional Application
62350419
· Jun 15, 2016
References Cited (400)
US 4812397A
· Wesibart
· 1989
[cited by applicant]
US 4952394A
· Senter
· 1990
[cited by applicant]
US 5618528A
· Cooper
· 1997
[cited by applicant]
US 5780033A
· Torchilin
· 1998
[cited by applicant]
US 5883223A
· Gray
· 1999
[cited by applicant]
US 6004534A
· Langer
· 1999
[cited by applicant]
US 7189396B1
· Weisbart
· 2007
[cited by applicant]
US 9107950B2
· Borden
· 2015
[cited by applicant]
US 9283272B2
· Weisbart
· 2016
[cited by applicant]
US 9701740B2
· Hansen
· 2017
[cited by applicant]
US 20020090608A1
· Palese
· 2002
[cited by applicant]
US 20030083305A1
· Palese
· 2003
[cited by applicant]
US 20030109475A1
· Debs
· 2003
[cited by applicant]
US 20050256073A1
· Lipford
· 2005
[cited by applicant]
US 20060110740A1
· Hurwitz
· 2006
[cited by applicant]
US 20060263367A1
· Fey
· 2006
[cited by applicant]
US 20070166281A1
· Kosak
· 2007
[cited by applicant]
US 20080004561A1
· Genkin
· 2008
[cited by applicant]
US 20080085241A1
· Stassar
· 2008
[cited by applicant]
US 20090186802A1
· Bertrand
· 2009
[cited by applicant]
US 20100143358A1
· Weisbart
· 2010
[cited by applicant]
US 20110300164A1
· Lipford
· 2011
[cited by applicant]
US 20120010124A9
· Bertrand
· 2012
[cited by applicant]
US 20130137644A1
· Bertrand
· 2013
[cited by applicant]
US 20130225611A1
· Weis et al.
· 2013
[cited by applicant]
US 20160114058A1
· Weisbart
· 2016
[cited by applicant]
US 20170292961A1
· Hansen
· 2017
[cited by applicant]
US 20200129636A1
· Weisbart
· 2020
[cited by applicant]
US 20200199255A1
· Hansen
· 2020
[cited by applicant]
US 20200216568A1
· Campbell
· 2020
[cited by applicant]
US 20210137960A1
· Hansen et al.
· 2021
[cited by applicant]
US 20240166770A1
· Hansen et al.
· 2024
[cited by applicant]
EP 0437092
· 1991
[cited by applicant]
EP 0543653A1
· 1993
[cited by applicant]
EP 1666055
· 2006
[cited by applicant]
EP 3173428
· 2017
[cited by applicant]
EP 3773919
· 2021
[cited by applicant]
WO 9732602
· 1997
[cited by applicant]
WO 1997032602
· 1997
[cited by applicant]
WO 2004003019
· 2006
[cited by applicant]
WO 2008091911
· 2008
[cited by applicant]
WO 2008148063
· 2008
[cited by applicant]
WO 2009043031
· 2009
[cited by applicant]
WO 2009134027
· 2009
[cited by applicant]
WO 2009142326
· 2009
[cited by applicant]
WO 2009143865A1
· 2009
[cited by applicant]
WO 2010013836
· 2010
[cited by applicant]
WO 2010056043
· 2010
[cited by applicant]
WO 2010148010
· 2010
[cited by applicant]
WO 2010138769
· 2010
[cited by applicant]
WO 2011030116A1
· 2011
[cited by applicant]
WO 2011041721A1
· 2011
[cited by applicant]
WO 2012135831
· 2012
[cited by applicant]
WO 2012145125
· 2012
[cited by applicant]
WO 2012150543A1
· 2012
[cited by applicant]
WO 2013031718
· 2013
[cited by applicant]
WO 2013096835
· 2013
[cited by applicant]
WO 2013138662
· 2013
[cited by applicant]
WO 2013166487
· 2013
[cited by applicant]
WO 2013177428
· 2013
[cited by applicant]
WO 2014087023
· 2014
[cited by applicant]
WO 2014106001A2
· 2014
[cited by applicant]
WO 2014130722
· 2014
[cited by applicant]
WO 2014130723
· 2014
[cited by applicant]
WO 2015106290
· 2015
[cited by applicant]
WO 2015134607
· 2015
[cited by applicant]
WO 2015161142A1
· 2015
[cited by applicant]
WO 2015192092
· 2015
[cited by applicant]
WO 2016013870
· 2016
[cited by applicant]
WO 2016033321
· 2016
[cited by applicant]
WO 2016033324
· 2016
[cited by applicant]
WO 2017007120A1
· 2017
[cited by applicant]
WO 2017218824
· 2017
[cited by applicant]
WO 2017218825
· 2017
[cited by applicant]
WO 2018049237
· 2018
[cited by applicant]
WO 2018089835A1
· 2018
[cited by applicant]
WO 2019018426
· 2019
[cited by applicant]
WO 2019018428
· 2019
[cited by applicant]
WO 2019152806
· 2019
[cited by applicant]
WO 2019152808
· 2019
[cited by applicant]
WO 2019178532
· 2019
[cited by applicant]
WO 2019186141
· 2019
[cited by applicant]
WO 2020047344
· 2020
[cited by applicant]
WO 2020047345
· 2020
[cited by applicant]
WO 2020047353
· 2020
[cited by applicant]
Aboul-Fadl, “Antisense oligonucleotides: the state of the art”,
[cited by applicant]
Achuthan, et al., “Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species”,
[cited by applicant]
Adjei, “Blocking oncogenic Ras signaling for cancer therapy”,
[cited by applicant]
Aguilera, et al., “Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides”,
[cited by applicant]
Ahmed, et al., “Extracellular renal guanosine cyclic 3′5′-monophosphate modulates nitric oxide and pressure-induced natriuresis”,
[cited by applicant]
Alarcon-Segovia, “Antinuclear antibodies: to penetrate or not to penetrate, that was the question”,
[cited by applicant]
Allesen-Holm, et al., “A characterization of DNA release in Pseudomonas aeruginosa cultures and biofilms”,
[cited by applicant]
American Cancer Society, Cancer Facts & Figures, pp. 1-70 (2014).
[cited by applicant]
Andersen, et al., “Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients,”
[cited by applicant]
Apte, et al., “Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models”,
[cited by applicant]
Arnaudeau, et al., “DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells”,
[cited by applicant]
ATCC® CCI-86™ Raji, “
[cited by applicant]
ATCC® CRL-1651™ COS-7, “Cercopithecus aethiops kidney”, http://www.aroc.org/Products/ALL/CRL1651.aspx 1 page, retrieved from the internet Jul. 12, 2015.
[cited by applicant]
Barenholz, et al., “Doxil®—the first FDA-approved nano-drug: lessons learned”,
[cited by applicant]
Barka, et al., “Transduction of TAT-HA—galactosidase Fusion Protein into Salivary Gland-derived Cells and Organ Cultures of the Developing Gland, and into Rat Submandibular Gland in Vivo”,
[cited by applicant]
Barnes, “Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain”,
[cited by applicant]
Bassi, et al., “Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress”,
[cited by applicant]
Berglund, et al., “The epitope space of the human proteome”,
[cited by applicant]
Bernatsky, et al., “Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis”,
[cited by applicant]
Bernatsky, et al., “Cancer risk in systemic lupus: an updated international multi-centre cohort study”,
[cited by applicant]
Bernatsky, et al., “Decreased breast cancer risk in systemic lupus erythematosus: the search for a genetic basis continues”,
[cited by applicant]
Bernatsky, et al., “Prostate cancer in systemic lupus erythematosus”,
[cited by applicant]
Bernatsky, et al., “The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study”,
[cited by applicant]
Bindra, et al., “Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells”,
[cited by applicant]
Bisazza, et al., “Microbubble-Mediated Oxygen Delivey to Hypoxic Tissues as a New Therapeutic Device”,
[cited by applicant]
Bitzer, et al., “Sendai virus vectors as an emerging negative-strand RNA viral vector system”,
[cited by applicant]
Brorson, et al., “Mutational analysis of avidity and fine specificity of anti-levan antibodies”,
[cited by applicant]
Brummel, et al., “Probing the combining site of an anti-carbohydrate antibody by saturation-mutagenesis: role of the heavy-chain CDR3 residues”,
[cited by applicant]
Bryant, et al., “Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase”,
[cited by applicant]
Burks, et al., “In vitro scanning saturation mutagenesis of an antibody binding product”,
[cited by applicant]
Casset, et al., “Peptide mimetic of an anti-CD4 monoclonal antibody by rational design”,
[cited by applicant]
Celldex, CDX-011 Clinical program http://www.celldextherapeutics.com/wt/page/cds_011_breast?CMP=KNC-3GS620403736., retrieved from the interned Mar. 31, 2011.
[cited by applicant]
Chan, et al., “Targeting cancer with a cell-penetrating anti-DNA antibody”,
[cited by applicant]
Chauhan, et al., “Strategies for advancing cancer nanomedicine”,
[cited by applicant]
Chen, et al., “A lupus anti-DNA autoantibody mediates autocatalytic, targeted delivery of nanoparticles to tumors”,
[cited by applicant]
Chen, et al., “Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen”,
[cited by applicant]
Chi, et al., “Roles of ATP binding and ATP hydrolysis in human Rad51 recombinase function”,
[cited by applicant]
Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins”,
[cited by applicant]
Chow et al., “Cancer nanomedicine: from drug delivery to imaging”,
[cited by applicant]
Cleaver, et al., “Phosphorylated H2Ax is not an unambiguous marker for DNSA double-strand breaks”,
[cited by applicant]
Coffin, “HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy”,
[cited by applicant]
Colburn et al., “Serum antibodies as a marker for SLE disease activity and pathogen potential”,
[cited by applicant]
Colburn, et al., “Anti-guanosine antibodies in murine and human lupus have the internal image of G-binding proteins”,
[cited by applicant]
Colburn, et al., “Circulating antibodies to guanosine in systemic lupus erythematosus: correlation with nephritis and polyserositis by acute and longitudinal analyses”,
[cited by applicant]
Coleman, “Effects of amino acid sequence changes on antibody-antigen interactions”,
[cited by applicant]
Collingridge, et al., “Pentoxifylline improves the oxygenation and radiarion response of BA 1112 rat rhabdomyosarcomas and EMT6 mouse mammary carcinomas”,
[cited by applicant]
Collins, et al., “Viral vectors in cancer immunotherapy: which vector for which strategy”,
[cited by applicant]
Corada, et al., “Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability”,
[cited by applicant]
Croy et al., “Polymeric micelles for drug delivery”,
[cited by applicant]
Cuesta, et al., “Multivalent antibodies: when design surpasses evolution”,
[cited by applicant]
Dausch, et al., “Comparative study of treatment of the dry eye syndrome due to disturbances of the tear film lipid layer with lipid-containing tear substitutes”,
[cited by applicant]
Dean, et al, “Current advances in the translation of cascular tissue engineering to the treatment of pediatric congenital heart disease”,
[cited by applicant]
Demers, et al., “Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis”,
[cited by applicant]
DePascalis, et al., “Grafting of abbreviated complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody”,
[cited by applicant]
Derossi, et al., “The third helix of the Antennapedia homeodomain translocates through biological membranes”,
[cited by applicant]
Deutsch, et al., “Guanosine possesses specific modulatory effects on NMDA receptor-mediated neurotransmission in intact mice,”
[cited by applicant]
Deyev, et al., “Multivalemcy: the hallmark of antibodies used for optimization of tumor targeting by design”,
[cited by applicant]
Dimri, et al., “A biomarker that identifies senescent human cells in culture and in aging skin in vivo”,
[cited by applicant]
Dowdy, et al., “Cationic PTD/CPP-mediated macromolecular delivery: charging into the cell,”
[cited by applicant]
Dray , et al., “Molecular basis for enhancement of the meiotic DMC1 recombinase by RAD51 associated protein 1 (RAD51AP1)”,
[cited by applicant]
Eivazova, et al., “Specificity and binding kinetics of murine lupus anti-DNA monoclonal antibodies implicate different stimuli for their production”,
[cited by applicant]
Elbayoumi, et al., “Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents,”
[cited by applicant]
Farmer, et al., “Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy”,
[cited by applicant]
Feng, et al., “Rad52 inactivation is synthetically lethal with BRCA2 deficiency”,
[cited by applicant]
Fiorica, “The role of topotecan in the treatment of advanced cervical cancer”,
[cited by applicant]
Ford, “Lupus antibody tops cancer cells”,
[cited by applicant]
Foroutan, et al., “Molecular cytogenetic analysis of chemoresistant non-Hodgkin's lymphoma patients with p53 abnormalities using fluorescence in situ hybridisation and comparative genomic hybridisation”,
[cited by applicant]
Frankel and Pabo, “Cellular uptake of the tat protein from human immunodeficiency virus”,
[cited by applicant]
Fujita, et al., “Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid),”
[cited by applicant]
Fusaki, et al., “Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome”,
[cited by applicant]
Genbank, Accession No., L16981.1, “
[cited by applicant]
Genbank, Accession No., AAA65681.1, “immunoglobulin light chain, partial [Mus musculus]”, 2 pages, First available May 2, 1995, accessed Mar. 28, 2016.
[cited by applicant]
Genbank, Accession No., AAA65682.1, “This CDS feature is included to show the translation of the of the corresponding V_region. Presently translation qualifiers on V_regions features are illegal, partial [Mus musculus]”…
[cited by applicant]
Genbank, Accession No., AAA65679.1, immunoglobulin heavy chain, partial [Mus musculus], 2 pages, accessed Nov. 30, 2009, updated Mar. 6, 2012, first appeared May 1, 1995.
[cited by applicant]
Gregoriadis et al., “Entrapment of proteins in liposomes prevents allergic reactions in pre-immunised mice”,
[cited by applicant]
Gregoriadis et al., “Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases”,
[cited by applicant]
Gregoriadis, “Engineering liposomes for drug delivery: progress and problems”,
[cited by applicant]
Gregoriadis, “The carrier potential of liposomes in biology and medicine (second of two parts)”,
[cited by applicant]
Gregoriadis, et al., “Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids”,
[cited by applicant]
Grudzien-Nogalska, et al., “Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells”,
[cited by applicant]
Gruhne, et al., “Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints”,
[cited by applicant]
Gu, et al., “Genetic determinants of autoimmune disease and coronary vasculitis in the MRL-lpr/lpr mouse model of systemic lupus erythematosus”,
[cited by applicant]
Gysin, et al., “Therapeutic strategies for targeting ras proteins”,
[cited by applicant]
Hacein-Bey-Abina, et al., “LMO-2associated clonal T cell proliferation in two patients after gene therapy for SCID-X1”,
[cited by applicant]
Halazonetis, et al., “An oncogene-induced DNA damage model for cancer development”,
[cited by applicant]
Han, et al., “Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging”,
[cited by applicant]
Hansen, et al. “Antibody mediated transduction of therapeutic proteins into living cells”,
[cited by applicant]
Hansen, et al., “Antibody-mediated Hsp70 protein therapy”,
[cited by applicant]
Hansen, et al., “Antibody-mediated p53 protein therapy prevents liver metastasis in vivo”,
[cited by applicant]
Hansen, et al., “Intranuclear protein transduction through a nucleoside salvage pathway”,
[cited by applicant]
Hansen, et al., “Targeting cancer with a lupus autoantibody”,
[cited by applicant]
Harrington, et al., “VX-680, a ptent and selective small-molecule inhibitor of aurora kinases suppresses tumor growth in vivo”,
[cited by applicant]
Hawes, et al., “Extracellular DNA: A Bridge to Cancer”,
[cited by applicant]
Hayflick, et al., “The limited in vitro lifetime of human diploid cell strains”,
[cited by applicant]
Ho, et al., “Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo”,
[cited by applicant]
Hoeijmakers, “Dna damage, aging, and cancer”,
[cited by applicant]
Holm, et al., “Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1”,
[cited by applicant]
Holtkemp, et al., “Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells”,
[cited by applicant]
Hrkach, et al., “Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile”,
[cited by applicant]
Hucl, et al., “A syngeneic variance library for functional annotation of human variation: application to BRCA2”,
[cited by applicant]
Immordino, et al., “Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential”,
[cited by applicant]
Isenberg, et al., “Fifty years of anti-ds DNA antibodies: are we approaching journey's end”,
[cited by applicant]
Itoh, et al., “Diagnostic use of anti-modified nucleoside monoclonal antibody”,
[cited by applicant]
Jackson, et al., “Guanosine regulates adenosine levels in the kidney”
[cited by applicant]
Jain, “Transport of molecules across tumor vasculature”,
[cited by applicant]
Jain, et al., “Engineering antibodies for clinical applications”,
[cited by applicant]
Jang, et al., “Drug delivery and transport to solid tumors”,
[cited by applicant]
Jang, et al., “The structural basis for DNA binding by an anti-DNA autoantibody”,
[cited by applicant]
Jordan, et al., Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations,
[cited by applicant]
Kabat, et al., “Sequences of proteins of Immunological Interest”,
[cited by applicant]
Kabouridis, “Biological applications of protein transduction technology”,
[cited by applicant]
Kaelin, Jr., et al., “The concept of synthetic lethality in the context of anticancer therapy”,
[cited by applicant]
Kane, et al., “Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines”,
[cited by applicant]
Kay, “State of the art gene-based therapies: the road ahead”,
[cited by applicant]
Kellner, et al., “Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions”,
[cited by applicant]
Kelly, et al., “Targeted liposomal drug delivery to monocytes and macrophages”,
[cited by applicant]
Kim, et al., “Heavy and light chain variable single domains of an anti-DNA binding antibody hydrolyze both double- and single-stranded DNAs without sequence specificity”,
[cited by applicant]
Kobayashi, et al., “Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody”,
[cited by applicant]
Kocbek, et al., “Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody”,
[cited by applicant]
Kozyr, et al., “Anti-DNA autoantibodies reveal toxicity to tumor cell lines”,
[cited by applicant]
Kulkarin-Kale, et al., “CEP: a conformational epitope prediction server”,
[cited by applicant]
Kumar, et al., “Molecular cloning and expression of the fabs of human autoantibodies in
[cited by applicant]
Lallemand, et al., “Cyclosporine A delivery to the eye: a pharmaceutical challenge”,
[cited by applicant]
Lau, et al., “Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase”,
[cited by applicant]
Lee, et al., “A new therapy concept with a Liposome Eye Spray for the treatment of dry eye”,
[cited by applicant]
Lee, et al., “Cell-penetrating autoantibody induces caspase-mediated apoptosis through catalytic hydrolysis of DNA”,
[cited by applicant]
Lee, et al., “Gene silencing by cell-penetrating, sequence-selective and nucleic-acid hydrolyzing”,
[cited by applicant]
Lei, et al., “Targeted Delivery of Doxorubicin by PLGA Nanoparticles Increases Drug Uptake in Cancer Cell Lines”, 26th Southern Biomedical Engineering Conference SBEC 2010, Apr. 30-May 2, 2010, College Park, Maryland, U…
[cited by applicant]
Levitt, et al., “PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2”,
[cited by applicant]
Lewitzky, et al., “Reprogramming somatic cells towards pluripotency by defined factors”,
[cited by applicant]
Li, et al., “Homologous recombination in DNA repair and DNA damage tolerance”,
[cited by applicant]
Li, et al., “PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer”,
[cited by applicant]
Liao, et al., “The comet assay: a sensitive method for detecting DNA damage in individual cells”,
[cited by applicant]
Lin, et al., “Improved affinity of a chicken single-chain antibody to avian infectious bronchitis virus by site-directed mutagenesis of complementarity-determining region H3”,
[cited by applicant]
Lisi, et al., “Advances in the understanding of the Fc gamma receptors-mediated autoantibodies uptake”,
[cited by applicant]
Liu, et al., “A novel bivalent single-chain variable fragment (scFV) inhibits the action of tumor necrosis factor [alpha]”,
[cited by applicant]
Liu, et al., “Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor,”
[cited by applicant]
Liu, et al., “Poly(ω-pentadecalactone-co-butylene-co-succinate) Nanoparticles as Biodegradable Carriers for Camptothecin Delivery”,
[cited by applicant]
Ma, et al., “Antibodies to guanosine triphosphate misidentified as anti-double-stranded DNA antibodies in a patient with antinuclear antibody-negative lupus, due to buckling of insolubilized assay DNA”,
[cited by applicant]
MacCallum, et al., “Antibody-antigen interactions: Contact analysis and binding site topography”,
[cited by applicant]
Maeda, et al., “Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review”,
[cited by applicant]
Mariuzza, et al., “The structural basis of antigen-antibody recognition”,
[cited by applicant]
Mccabe, et al., “BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency”,
[cited by applicant]
McCarthy, et al., “Altering the fine specificity of an anti-legionella single chain antibody by a single amino acid insertion”,
[cited by applicant]
McEllin, et al., “PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors”,
[cited by applicant]
Minko, et al., “New generation of liposomal drugs for cancer”,
[cited by applicant]
Molfetta, et al., “Regulation of fc receptor endocytic trafficking by ubiquitination”
[cited by applicant]
Moynahan, et al., “BRCA2 is required for homology-directed repair of chromosomal breaks”,
[cited by applicant]
Muller, et al., “TransMabs: cell-penetrating antibodies, the next generation”,
[cited by applicant]
Nakanishi, et al., “Development of sendai virus vectors and their potential applications in gene therapy and regenerative medicine”,
[cited by applicant]
Noble, et al., “A cell-penetrating nucleoltyic lupus autoantibody damages DNA and is toxic to BRCA2-deficient cancer cells” poster presented at the Proceedings: AACR Annual Meeting 2014; Apr. 5-9, San Diego, CA (2014b).
[cited by applicant]
Noble, et al., “A cell-penetrating nucleolytic lupus autoantibody damages DNA and is toxic to BRCA2-deficient cancer cells”, Abstract 4220,
[cited by applicant]
Noble, et al., “A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells”,
[cited by applicant]
Noble, et al., “DNA-damaging autoantibodies and cancer: the lupus butterfly theory”,
[cited by applicant]
Noble, et al., “Optimizing a lupus autoantibody for targeted cancer therapy”,
[cited by applicant]
Okita, et al., “Induction of pluripotency by defined factors”,
[cited by applicant]
Okshevsky, et al., “Extracellular DNA as a target for biofilm control”,
[cited by applicant]
Padlan, “X-ray crystallography of anti-bodies”,
[cited by applicant]
Park, et al., “PEGylated PLGA nanoparticles for the improved delivery of doxorubicin”,
[cited by applicant]
PARP Inhibitor, http://www.parp-inhibitors.com, retrieved from the internet Mar. 31, 2011.
[cited by applicant]
Pavlovic, et al., “Pathogenic and epiphenomenal anti-DNA antibodies in SLE”,
[cited by applicant]
Porter, et al., “Chimeric antigen receptor-midified T cells in chronic lymphoid leukemia”,
[cited by applicant]
Puc, et al., “PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells”,
[cited by applicant]
Rabinovich, et al., “Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes”,
[cited by applicant]
Rabinovich, et al., “Synthetic messenger RNA as a tool for gene therapy”,
[cited by applicant]
Rahman and Isenberg, “Systemic lupus erythematosus”,
[cited by applicant]
Rathbone, et al., “Neurotrophic effects of extracellular guanosine”
[cited by applicant]
Ratnam, et al., “Current development of clinical inhibitors of poly (ADP-ribose) polymerase in oncology”,
[cited by applicant]
Ritter, et al., “Gene therapy in transplantation: Toward clinical trials”,
[cited by applicant]
Rivadeneyra-Espinoza, et al., “Cell-penetrating anti-native DNA antibodies trigger apoptosis through both the neglect and programmed pathways”,
[cited by applicant]
Rudikoff, et al., “Single amino substitution altering antigen-binding specificity”,
[cited by applicant]
Sakai, et al., “Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma”,
[cited by applicant]
Sancar, et al., “Molecular mechanisms of mammalian NA repair and the DNA damage checkpoints”,
[cited by applicant]
Sano, et al., “Dna isolated from DNA/anti-DNA antibody immune complexes in systemic lupus erythematosus is rich in guanine-cytosine content”
[cited by applicant]
Sapra, et al., “Ligand-targeted liposomes for cancer treatment”,
[cited by applicant]
Sawant, et al., “Nanosized cancer cell-targeted polymeric immunomicelles loaded with superparamagnetic iron oxide particles”
[cited by applicant]
Scott, et al., “Antibody therapy of cancer”,
[cited by applicant]
Senge, “Immunoliposomes”,
[cited by applicant]
Service, et al., “Nanotechnology. Nanoparticle Trojan horses gallop from the lab into the clinic”,
[cited by applicant]
Shao, et al., “Reversibly crosslinked nanocarriers for on-demand drug delivery in cancer treatment”,
[cited by applicant]
Shin, et al., “Pharmacokinetics of guanosine in rats following intravenous or intramuscular administration of a 1:1 mixture of guanosine and acriflavine, a potential antitumor agent”
[cited by applicant]
Shuster, et. al., “DNA hydrolyzing autoantibodies”,
[cited by applicant]
Singh, et al., “A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival”,
[cited by applicant]
Skoulidis, et al., “Germline Brca2 heterozygosity promotes Kras(G12D)—driven carcinogenesis in a murine model of familial pancreatic cancer”,
[cited by applicant]
Sliwinska, et al., “Induction of senescence with doxorubicin leads to increased genomic instability of HCT116 cells”,
[cited by applicant]
Smith-Gill, et al., “Contributions of immunoglobulin heavy and light chains to antibody specificity for lysozyme and two haptens”,
[cited by applicant]
Song, et al., “Light chain of natural antibody plays a dominant role in protein antigen binding”,
[cited by applicant]
Spertini, et al., “Idiotypic vaccination with a murine anti-dsDNA antibody: phase I study in patients with nonactive systemic lupus erythematosus with nephritis”,
[cited by applicant]
Stachelek, et al., “Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase beta is accentuated by BRCA2 mutation”,
[cited by applicant]
Stanulis-Praeger, et al., “Cellular senescence revisited: a review”,
[cited by applicant]
Steck, et al., “Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers”,
[cited by applicant]
Stepinski, et al., “Synthesis and properties of mRNA's containing the novel “anti-reverse” cap analogs 7-methyl(3′-O-methyl)GpppG and 7-methyl (3′-deoxy)GpppG”,
[cited by applicant]
Stollar, et al., “Nucleoside specificity in the carrier IgG-dependent induction of tolerance”,
[cited by applicant]
Stone, et al., “Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients”,
[cited by applicant]
Stroun, et al., “About the possible origin and mechanism of circulating DNA apoptosis and active DNA release”,
[cited by applicant]
Sueoka-Aragane, et al., “Correlation between plasma DNA and tumor status in an animal model”,
[cited by applicant]
Sugahara, et al., “Tissue-penetrating delivery of compounds and nanoparticles into tumors”,
[cited by applicant]
Sung, “Catalysis of ATP-dependent homologous DNA pairing and strand exchange by yeast RAD51 protein”,
[cited by applicant]
Sung, et al., “DNA strand exchange mediated by a RAD51-ssDNA nucleoprotein filament with polarity opposite to that of RecA”,
[cited by applicant]
Sung, et al., “Rad51 recombinase and recombination mediators”,
[cited by applicant]
Swystun, et al., “Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus”,
[cited by applicant]
Te Poele, et al., “DNA damage is able to induce senescence in tumor cells in vitro and in vivo”,
[cited by applicant]
Tewey, et al., “Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II”,
[cited by applicant]
Tyagi, et al., “Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes”,
[cited by applicant]
Tzartos, et al., “Epitope mapping by antibody completion”,
[cited by applicant]
Uemura, et al., “Neurochemical analysis of focal ischemia in rats”,
[cited by applicant]
Vajdos, et al., “Comprehensive functional maps of the antigen-binding site of am amti-ErbB2 antibody obtained with shotgun scanning mutagenesis”,
[cited by applicant]
Vlietstra, et al., “Frequent inactivation of PTEN in prostate cancer cell lines and xenografts”,
[cited by applicant]
Von Maltzahn, et al., “Nanoparticles that communicate in vivo to amplify tumour targeting”,
[cited by applicant]
Wadia and Stan, “Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft micropinocytosis”,
[cited by applicant]
Walpita, et al., “Reverse genetics of negative-stranded RNA viruses: a global perspective”, FEMS Microbiol. Lett., 244(1):9-18 (2005).
[cited by applicant]
Wang, Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair,
[cited by applicant]
Ward, et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from
[cited by applicant]
Warren, et al., “Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA”,
[cited by applicant]
Weisbart, “Antibody-mediated transduction of p53 selectively kills cancer cells”,
[cited by applicant]
Weisbart, et al. “A conserved anti-DNA antibody idiotype associated with nephritis in murine and human systemic lupus erythematosus”,
[cited by applicant]
Weisbart, et al. “Novel protein transfection of primary rat cortical neurons using an antibody that penetrates living cells”,
[cited by applicant]
Weisbart, et al., “A cell-penetrating bispecific antibody for therapeutic regulation of intracellular targets”,
[cited by applicant]
Weisbart, et al., “An autoantibody is modified for use as a delivery system to target the cell nucleus: therapeutic implications”,
[cited by applicant]
Weisbart, et al., “Cell type specific targeted intracellular delivery into muscle of a monoclonal antibody that binds myosin IIb”,
[cited by applicant]
Weisbart, et al., “Construction and expression of a bispecific single-chain antibody that penetrates mutant p53 colon cancer cells and binds p53”,
[cited by applicant]
Weisbart, et al., “DNA-dependent targeting of cell nuclei by a lupus autoantibody”,
[cited by applicant]
Weisbart, et al., “Nuclear delivery of p53 C-terminal peptides into cancer cells using scFv fragments of a monoclonal antibody that penetrates living cells”,
[cited by applicant]
Wen, et al., “Extracellular DNA in pancreatic cancer promotes cell invasion and metastasis”,
[cited by applicant]
Wender, et al., “The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters”,
[cited by applicant]
Whitchurch, et al., “Extracellular DNA required for bacterial biofilm formation”,
[cited by applicant]
Whitney, et al., “Parallel in vivo and in vitro selection using phage display identifies protease-dependent tumor-targeting peptides”,
[cited by applicant]
Williams, “DNA hydrolysis mechanism and reactivity”,
[cited by applicant]
Wu, et al., “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues”,
[cited by applicant]
Wu, et al., “pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery”,
[cited by applicant]
Xu, et al., “Dual DNA unwinding activities of the Rothmund-Thomson syndrome protein, RECQ4”,
[cited by applicant]
Xu, et al., “MCM10 mediates RECQ4 association with MCM2-7 helicase complex during DNA replication”,
[cited by applicant]
Yee, et al., “The fine specificity of IgG antiguanosine antibodies in systemic lupus erythematosus”,
[cited by applicant]
Yeh, et al., “A Targeting Microbubble for Ultrasound Molecular Imaging,”
[cited by applicant]
Yoder, et al., “The base excision repair pathway is required for efficient lentivirus integration”,
[cited by applicant]
Yoshizaki, et al., “Naked sendai virus vector lacking all of the envelope-related genes: reduced cytopathogenicity and immunogenicity”,
[cited by applicant]
Young, et al., “Targeting K-ras cancer cells with a lupus anti-guanosine antibody”,
[cited by applicant]
Yung, et al., “Anti-DNA antibodies in the pathogenesis of lupus nephritis—The emerging mechanisms”,
[cited by applicant]
Zack, et al. “Mechanisms of cellular penetration and nuclear localization of an anti-double strand DNA autoantibody”,
[cited by applicant]
Zack, et al., “DNA mimics a self-protein that may be a target for some anti-DNA antibodies in systemic lupus erythematosus”,
[cited by applicant]
Zack, et al., “Novel structural features of autoantibodies in murine lupus: a possible superantigen binding site”,
[cited by applicant]
Zack, et al., “Two kappa immunoglobulin light chains are secreted by an anti-DNA hybridoma: implications for isotypic exclusion”,
[cited by applicant]
Zhan, et al., “Recombinant Fv-Hsp70 protein mediates neuroprotection after focal cerebral ischemia in rats”,
[cited by applicant]
Zhou, et al., “Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma”,
[cited by applicant]
Zhou, et al., “Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors”,
[cited by applicant]
Zhu, et al., “Matrix Metalloprotease 2-Rsponsive Multifunctional Liposomal Nanocarrier for Enhanced Tumor Targeting”,
[cited by applicant]
International Search report for corresponding PCT application PCT/US2017/037753 mailed Oct. 23, 2017.
[cited by applicant]
Andersen, et al.,“Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients,” Journal of Investigative Medicine (2009).
[cited by applicant]
Barenholz, et al., “Doxil®—the first FDA-approved nano-drug: lessons learned”, J Control Release, 160(2):117-34 (2012).
[cited by applicant]
Genbank, Accession No., L16981.1, “Mouse Ig rearranged L-chain gene, partial cds”, 1 page, accessed Nov. 30, 2009, updated Mar. 6, 2012, first appeared May 1, 1995.
[cited by applicant]
Kelly, et al., “Targeted liposomal drug delivery to monocytes and macrophages”, J. Drug Deliv., 2011(727241):1-11 (2011).
[cited by applicant]
Noble, et al., “A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells”, Sci Rep-Uk, 4:5958. doi: 10.1038/srep05958 (2014a).
[cited by applicant]
Pavlovic, et al., “Pathogenic and epiphenomenal anti-DNA antibodies in SLE”, Autoimmime Diseases, 2010:462841 1-18 (2010).
[cited by applicant]
Stollar, et al., “Nucleoside specificity in the carrier lgG-dependent induction of tolerance” J Immunol, 117:1308-1313 (1976).
[cited by applicant]
Weisbart, et al., “Novel protein transfection of primary rat cortical neurons using an antibody that penetrates living cells”, J Immunol., 164: 6020-6 (2000).
[cited by applicant]
Yee, et al., “The fine specificity of lgG antiguanosine antibodies in systemic lupus erythematosus”, Clin Immunol Immunopathol., 36(2):161-7 (1985).
[cited by applicant]
U.S. Appl. No. 16/967,109, filed Aug. 3, 2020, Hansen.
[cited by applicant]
U.S. Appl. No. 16/967,119, filed Aug. 3, 2020, Hansen.
[cited by applicant]
Alarcon-Segovia, et al., “Antibody penetration into living cells. I. Intranuclear immunoglobulin in peripheral blood mononuclear cells in mixed connective tissue disease and systemnic lupus erythematosus”, Clin. Exp. Im…
[cited by applicant]
Allemann, et al., “Drug-loaded nanoparticles: Preparation methods and drug targeting issues”, European Journal of Pharmaceuticals and Biopharmaceuticals, 39(5): 173-191 (1993).
[cited by applicant]
Avrameas, et al., “Polyreactive anti-DNA monoclonal antibodies and a derived peptide as vectors for the intracytoplasmic and intranuclear translocation of macromolecules” Proc. Natl. Acad. Sci. U.S.A., 95(10):5601-5606 …
[cited by applicant]
Axup, “Synthesis of site-specific antibody-drug conjugates using unnatural amino acids”, Proceedings of the National Academy of Sciences, 109 (40): 16101-6 (2012).
[cited by applicant]
Bao, et al., “PLGA-PLL-PEG-Tf-based targeted nanoparticles drug delivery system enhance antitumor efficacy via intrinsic apoptosis pathway”, International Journal of Nanomedicine, 10: 557-66 (2015).
[cited by applicant]
Barthelemy, et al., “Comprehensive Analysis of the Factors Contributing to the Stability and Solubility of Autonomous Human VH Domains” Journal of Biological Chemistry, 283:3639-3654 (2008).
[cited by applicant]
Beibor, et al., “Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent” Journal of Molecula…
[cited by applicant]
Bertram, “Functionalized poly(lactic-co-glycolic acid) enhances drug delivery and provides chemical moieties for surface engineering while preserving biocompatibility”, Acta Biomater. 5:2860-71 (2009).
[cited by applicant]
Caster, et al., “Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity”, Nanoscale, 7(6):2805-2011 (2015).
[cited by applicant]
Chan, et al., “Combining intracellular antibodies to restore function of mutated p53 in cancer” Int. J. Cancer, 138(1):182-6 (2016).
[cited by applicant]
Choi, et al., “Predicting antibody complementarity determining region structures without classification”, Molecular BioSystems, 7:3327-3334 (2011).
[cited by applicant]
De Genst, et al., “Antibody repertoire development in carnelids” Developmental and Comparative Immunology, 30:187-98 (2006).
[cited by applicant]
Deng et al., “In vivo cell penetration and intracellular transport of anti-Sm and anti-La autoantibodies”, Int Immunol 12, 415-423 (2000).
[cited by applicant]
GenBank Acc. No. BAG36664.1, unnamed protein product [
[cited by applicant]
Genbank AF289183.1., Mus musculus anti-DNA monoclonal autoantibody G1-5 light chain variable region mRNA, partial cds.
[cited by applicant]
GenBank: L34051.1—Mouse Ig rearranged kappa-chain mRNA V-region.
[cited by applicant]
Golan et al., “Penetration of Autoantibodies into Living Epithelial Cells”, J Invest Dermatol 100, 316-322 (1993).
[cited by applicant]
Griffiths, et al., “Human anti-self antibodies with high specificity from phage display libraries”, The EMBO Journal, 12:725-734 (1993).
[cited by applicant]
Hong, et al., “pH-sensitive poly (histidine)-PEG/DSP-PEG copolymer micelles for cytosolic drug delivery”, Biomaterials, 34(4):1213-1222 (2013).
[cited by applicant]
Huang, et al., “Complications mimicking lupus flare-up in a uremic patient undergoing pegylated liposomal doxorubicin therapy for cervical cancer”, Anti-Cancer Drugs, 15:239-241 (2004).
[cited by applicant]
Im et al., “Cell- and nuclear-penetrating anti-dsDNA autoantibodies have multiple arginines in CDR3 of VH and increase cellular level of pERK and Bcl-2 in mesanglal cells”, Mol Immunol 67, 377-387 (2015).
[cited by applicant]
Im et al., “Development of single-chain Fv of antibody to DNA as intracellular delivery vehicle”, Animal Cells and Systems 21, 382-387 (2017).
[cited by applicant]
Isenberg, et al., “Detection Of Cross-Reactive Anti-Dna Antibody Idiotypes In The Serum Of Systemic Lupus Erythematosus Patients And Of Their Relatives”, Arthritis Rheum 28, 999-1007 (1985).
[cited by applicant]
Jang, et al., “A nucleic acid-hydrolyzing antibody penetrates into cells via caveolae-mediated endocytosis, localizes in the cytosol and exhibits cytotoxicity”, Cell Mol. Life Sci., 66:1985-97 (2009).
[cited by applicant]
Klimka, et al., “Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning”, British Journal of Cancer, 83:252-260 (2000).
[cited by applicant]